Silver-nanoparticle-mediated therapies in the treatment of pancreatic cancer by Foulkes, Rachel et al.
Silver Nanoparticle-Mediated Therapies in the 
Treatment of Pancreatic Cancer  
Rachel Foulkes, Mohsen Al Asgari, Anthony Curtis, Clare Hoskins* 
Institute of Science and Technology in Medicine, Keele University, Keele, Staffordshire, ST5 5BG, 
UK 
Keywords: Pancreatic cancer, silver nanoparticles, cancer therapy, thermal therapy, antimicrobial, 
drug delivery 
Abstract 
Pancreatic cancer is an extremely aggressive disease for which patient prognosis is poor and 
survival is extremely unlikely. It is an extremely under-represented cancer in the research field, due 
to the dense tumors formed and complexities surrounding treatment requirements.  The use of 
nanomedicines in cancer therapy has been explored over the past few decades. Such nanomedicines 
are slowly coming to fruition in the clinical setting. One such platform which may possess promise 
in the fight against pancreatic cancer is the use of colloidal silver. Silver nanoparticles have shown 
potential in other cancer types over a host of treatment strategies and these are likely to be 
translatable into pancreatic cancer. This review will focus on the potential use of silver 
nanoparticles in pancreatic cancer therapy, reporting on a range of different strategies being 
employed which may be directly applicable in improving the clinical outcomes for pancreatic 
cancer patients. 
  
 Introduction 
Cancer is a global problem, with a high incidence and mortality. The increases in occurrence of 
many types of cancers can be attributed to the increasingly ageing population and an increase in 
other significant and varied risk factors [1]. Pancreatic cancer involves the uncontrolled growth of 
malignant cells, often leading to the formation of tumors. Pancreatic cancer occurs most often in 
people between the ages of 40 and 80 [2]. According to the most recently published edition of 
Cancer Statistics, the survival rates for pancreatic cancer are the lowest of all cancers, with patients 
from the United States having only an 8% chance of survival [2]. A study by Bray et al. looked at 
pancreatic cancer on a global scale, determining that there were 458,918 new cases of pancreatic 
cancer and 432,243 deaths, showing the number of deaths is as high as the incidence [1]. 
Additionally, the same study determined that pancreatic cancer was the 7th leading cause of cancer-
related death worldwide in both men and women, with a proportion of sufferers being men.  
 There are several different reasons why survival rates of pancreatic cancer are so dire, 
including lack of early symptoms, making diagnosis very difficult until the cancer has progressed 
[3,4], minimal response from the immune system, especially with some immune cells being 
hijacked by tumors [3, 4], metastasis developing early in the disease progression [4, 5], the lack of 
biomarkers, and resistance to chemotherapeutics [6,7]. Additionally, there are no established causes 
of pancreatic cancer, but some risk factors have been identified, including smoking [4,8], obesity 
[5,9,10,11], heavy alcohol consumption [7,8,12,13], long-term diabetes [10,1114,15], and some 
hereditary factors [12,13,16,17]. There has been some evidence for a genetic basis for pancreatic 
cancer, due to there being heterogeneity found in tumor tissues and metastasised tissues [14,18]. 
There is also evidence that there are genetic variations between individual tumors, known as 
intratumoral heterogenicity [6,15]. 
Although diagnosis during the early stages can be difficult, there are several techniques that can be 
utilised to diagnose pancreatic cancer including biopsy, fine needle aspiration and magnetic 
resonance imaging [9,16].  
 Over half of patients with pancreatic cancer have either locally advanced cancer or 
metastatic cancer [3,17] and over 90% of patients with pancreatic cancer have Pancreatic Ductal 
Adenocarcinoma (PDAC), developing from pancreatic exocrine cells [19]. PDAC is one of the most 
aggressive malignant cancers and is projected to become the second greatest cause of cancer-related 
death by 2030 in the United States [20]. A key characteristic of PDAC is the appearance of 
precursor lesions, as documented by Matthaei et al., Wu et al., and Macgregor-Das and Iacobuzio-
Donahue [21-23]. These lesions are graded according to the level of potentially cancerous cells 
present, numbered 1 to 3, where 1 indicates low grade dysplasia and 3 high grade dysplasia [24]. 
Metastasis is common in pancreatic cancer, especially for patients with PDAC of which 90% 
present with metastasis at death [25], and common sites of spread including the peritoneum, liver 
and lungs [3]. Alongside being the most prevalent pancreatic cancer, PDAC has one of the greatest 
mortality rates of all cancer types, with a consistent 6% 5-year survival rate [26]. 
 
Cancer therapies: History and Future Prospects 
  Although various therapeutics have been trialled for the treatment of for pancreatic cancer 
tumors, the more standard chemotherapeutics and radiotherapy are known to be ineffective due to 
resistance [27]. Hence, gemcitabine remains a front-line treatment, though it only prolongs the life 
of patients rather than being a cure [28]. Gemcitabine (2’,2’-difluorodeoxycytidine) (Figure 1) is 
used to treat multiple cancer types, including pancreatic, lung and breast cancers [29]. However, 
gemcitabine has been recently faced with resistance in a similar manner to other traditional 
chemotherapies. To overcome this, there have been several attempts to combine gemcitabine with 
other cancer therapeutics as summarised in Table 1. 
  A study by Reni et al. combined gemcitabine with 5-fluoruracil (5-FU), cisplatin, and 
epirubicin for patients with advanced pancreatic cancer [30]. They determined that there was a 
progression free survival (PFS) of 4 months for 60% of patients taking the combination of drugs 
compared to 28% for those taking gemcitabine alone. They also determined that 11.5% of patients 
on the combination of drugs had an overall 2-year survival compared to 2.1% of patients on 
gemcitabine alone. However, a key problem identified within this study is the short period of time 
they used for PFS. The majority of studies find a median value for their PFS, giving a greater 
indication of the efficacy of their drug or combination of drugs.    
 Cunningham et al. combined gemcitabine with capecitabine, which gave an improved 
progression free survival (PFS) for patients with advanced pancreatic cancer, with a median 
survival of 7.1 months compared to a median survival of 6.2 months for patients on gemcitabine 
monotherapies [31] They also determined that there was an overall PFS of 5.3 and 3.8 months for 
gemcitabine-capecitabine and gemcitabine alone respectively. Grade 3 (severe) and grade 4 
(potentially life threatening) side effects generally decreased except in the case of neutropenia and 
hand-foot syndrome, which increased by 13% and 4% respectively. This approach is currently used 
in the UK as a therapy for pancreatic cancer. 
 Another treatment suggested was FOLFIRINOX, a combination of folinic acid, irinotecan 
and oxaliplatin [32]. Conroy et al. compared gemcitabine to FOLFIRINOX for patients with 
metastatic pancreatic cancer. They found a greater overall survival and a greater PFS of 11.1 and 
6.4 months respectively compared to gemcitabine’s 6.8-month overall survival and 3.3-month PFS 
[33]. However, there were more side effects noted when using FOLFIRINOX, with incidences of 
Grade 3 and 4 side effects, including neutropenia, thrombocytopenia and sensory neuropathy all 
increasing, with no statistics to show how much worse these side effects are in patients. This 
increase in prevalence of side effects indicates that FOLFIRINOX has a much higher toxicity to 
healthy cells and was also found to only work for around 30-40% of patients [33].  
  A study by von Hoff et al. used a combination of gemcitabine and nab-paclitaxel 
(Abraxane®) to treat patients with metastatic pancreatic adenocarcinoma and found a 1.8-month 
greater survival than using gemcitabine alone, but this is only a small improvement overall [34]. 
They also found a median PFS of 5.5 months compared to 3.7 months for gemcitabine alone. There 
was an increase in the percentage of some grade 3 and 4 side effects compared to gemcitabine 
alone. These included neutropenia (11% increase), fatigue (10% increase) and neuropathy (16% 
increase).  
A follow up to this study by Reni et al. used gemcitabine-nab-paclitaxel alongside cisplatin 
and capecitabine (PAXG) compared to nab-paclitaxel-gemcitabine (AG) [35]. There was an 
increase in the median PFS of patients taking the PAXG compared to the AG, 12.5 and 9.9 months 
respectively. As well as this, the median survival was found to be very similar for both treatments, 
with PAXG patients having 20.7 months and AG patients 19.1 months. They also noted that there 
was a decrease in grade 3 and 4 side effects, except for neutropenia and cholangitis, which 
increased by 15% and 1% respectively. 
 Although there has been some success in increasing the life expectancy of patients with 
pancreatic cancer, with the studies listed here showing a general improvement in median PFS and 
overall survival, the majority of these treatments provide no cure. They are mainly used to extend 
the life of patients and attempt to improve their quality of life. There are also issues with current 
therapeutics as all of these studies reported several side effects, mainly grade 3-4, commonly 
attributed to damage to healthy cells caused by the drugs, which could be avoided using a more 
targeted delivery system. The only treatment currently available that provides any form of “cure” is 
surgical resection. Surgical resection is, however, only possible for around 15% of patients and only 
in the early stages of pancreatic cancer [36] and is subsequently followed by chemotherapy [37]. 
However, this is still unsuccessful in most cases as 80% of patients relapse and there is a 5-year 
patient survival rate, despite undergoing chemotherapy after surgical resection [38,39].   
 
Pancreatic Tumors, the Tumor Microenvironment and Resistance to Chemotherapeutics 
  One of the initial problems with tumors and chemotherapeutic resistance is the entry of 
chemotherapeutics into tumor cells. The dense stroma formed by pancreatic cancers often hinder 
drug or particulate penetration into the tumor microenvironment where the rapidly proliferating 
cells are located (Figure 2) [40]. There are other components that effect resistance to 
chemotherapeutics, including healthy cells in the tumour environment. There is substantial evidence 
that healthy cells in the tumor microenvironment also increase drug resistance to anticancer agents 
[41-43]. In addition to this, it has been observed that some fibroblasts have the ability to confer 
resistance to anticancer agents, as in Gellar et al., who discovered that the combination of human 
dermal fibroblasts and colorectal and pancreatic cancer cell lines gave the cancer cells greater 
resistance to gemcitabine [29].  As well as these, Li et al. discovered the presence of cancer stem 
cells in human pancreatic adenocarcinoma [44]. They identified the pancreatic cancer stem cells 
using the marker combination CD44+ CD24+ ESA and saw that these cells were able to create other 
differentiated cells or self-renew in mice. Another study by Hermann et al. identified cancer stem 
cells in pancreas tissues using the surface marker CD133 [45].  They noted that CD133+ expressing 
cells had high tumorgenicity in contrast to the majority of CD133- expressing cells, which did not 
cause tumor formation.  
  Several components of the tumor microenvironment have been associated with cancer 
resistance, participating in the initiation, progression and metastasis of cancer [46]. Tumor 
associated macrophages (TAM’s) play a role in pro-tumor activity. TAM’s are commonly recruited 
by a few different types of cytokines, including chemokines and vascular endothelial growth factor 
[47]. They are also known to have decreased tumoricidal activity and are able to produce several 
factors that promote angiogenesis, including cyclo-oxygenase-2 (COX-2)-derived prostaglandin E2 
and vascular endothelial growth factor [48]. More recently, TAM’s have been implicated in 
producing Sema4D, which promotes angiogenesis [49], and Gas6, which promotes the proliferation 
of cancer cells [50]. Tumor cell products can promote the pro-tumor abilities of TAM, some of 
which include CSF-1, IL-10 [51] and certain components of the extra-cellular matrix [52].  
  Hwang et al. determined that human pancreatic stellate cells increased tumor proliferation, 
invasion, and colony formation [53]. As well as this, they also determined that the COX-2 gene is 
altered in cancer cells and fibroblasts and highlighted the potential role of pancreatic stellate cells in 
causing stroma. Xu et al. completed a study to determine the role of pancreatic stellate cells using 
both in vitro and in vivo models [53]. They confirmed that these cells facilitate the metastasis and 
local growth of tumors, as well as their ability to travel to other sites with cancer cells.   
  Cancer associated fibroblasts (CAFs) have been identified to play two different roles in 
tumorigenesis. Erez et al. identified that CAFs can recruit macrophages to mediate inflammation 
and stimulate angiogenesis [54]. They were also able to identify a gene signature from CAF that 
cause their ability to promote tumor growth. CAFs have also been implicated in promoting the 
growth of tumors in multiple ways, including angiogenesis and extracellular matrix remodelling. 
 Another cause of tumor progression is chronic inflammation. A study by de Visser, Korets 
and Coussens looked into chronic inflammation, how it is mediated, and whether this led to 
initiation of cancer using a HPV16 mouse model [55]. They initially determined that 
hyperproliferation of cells occurs with inflammation and that B-lymphocytes played a key role in 
regulation of inflammation that could lead to the formation of malignant cells. These B-
lymphocytes were not found to enter the premalignant skin, hence were deemed to act an 
immunomodulatory manner.  
  Many different proteoglycans have also been implicated in cancer biology. Iozzo determined 
that heparin sulphate proteoglycan contributes to pro-angiogenic activity [56], and later determined 
that C-terminal fragments of other proteoglycans could act in an anti-angiogenic manner in two 
other studies [57,58]. Sanderson and Yang determined that glypicans have also been involved in 
various functions in tumors, including promotion/inhibition of cancer initiation and progression 
[59]. Filmus and Selleck have determined that syndecans participate in the same processes [60]. 
Iozzo and Schaefer found that small leucine-rich proteoglycans block the activity of receptor 
tyrosine kinases in tumors [61]. 
  The MYC oncogene has also been implicated in the formation of tumors, due to alterations 
in copy number variations, where genome sections repeat [62]. This gene has the ability to initiate 
and progress the formation of tumors alone, which has been seen in several studies [63,64]. A study 
by Mazur et al. also determined that the Notch2 protein is a modulator of MYC in PDAC as 
observed in several cell lines [65]. Their study also noted the increased expression of MYC in 
pancreatic precursor tumors. The study by Witkiewicz et al. determined that activity of MYC was 
amplified and confirmed that there was increased expression of MYC in precursor pancreatic 
lesions [62]. 
  PDAC in particular has several different characteristics including dense desmoplastic 
infiltration, common to solid tumors, along with stroma, associated with chemoresistance and 
furthering tumor progression [46]. In PDAC specifically, stroma makes up over 80% of the mass of 
tumors [66]. Pancreatic stellate cells have been proposed to be responsible for stroma formation 
[67], with these cells composing 4% of pancreas tissue [68]. In fact, an index for stroma activation 
is determined using a marker for the activated form of the pancreatic stellate cells in relation to 
collagen expression, where a larger value indicates a poorer patient prognosis, a marker commonly 
used for PDAC patients [69]. With multiple factors causing resistance to chemotherapy and other 
anti-cancer drug regiments, treating patients with pancreatic cancer has become much more 
difficult.  
 
Intratumoral bacteria and how they affect anti-cancer therapies 
  One of the most recently identified causes of resistance to cancer therapeutics involves 
intratumoral bacteria. Hypoxia and necrosis are common in tumour tissues, providing the perfect 
environment in which bacteria can easily enter and successfully colonise [70]. The oxygen pressure 
in tumors has been found much lower than in normal tissues, often being in the range of 0-20 
mmHg compared to the normal 20-100 mmHg, indicating hypoxia [71].  Hypoxia and necrosis 
occur due to fast tumor growth and poor oxygen supply due to poor vascularisation, creating an 
anaerobic environment in which bacteria can enter and colonise [72]. 
  The clinical use of gemcitabine has been impacted by the current levels of tumor resistance, 
especially by the presence of intratumoral bacteria. Lehouritis et al. looked into the effects of 
bacteria against several different chemotherapeutics, including gemcitabine [73].  They used CT26 
tumors which were then injected with E. coli and treated with gemcitabine. Those tumors showed 
an increased tumor volume and there was a significant decrease in survival compared to a control 
(17 days versus 28 days). Hence, these results indicated that gemcitabine was less effective in 
controlling tumor growth when bacteria were present. In a similar study by Geller et al., they 
filtered their fibroblast-conditioned medium and resistance to gemcitabine was lost, indicating the 
presence of something else which may mediate resistance [29]. They discovered the presence of 
Mycoplasma DNA in the human dermal fibroblasts they co-cultured with the cancer cell lines, with 
almost all of the bacteria present being Mycoplasma hyorhinis. Using a mouse model, they also 
determined that M. hyorhinis was able to infiltrate tumor cells and cause resistance to gemcitabine 
and can convert gemcitabine to 2’2-difluorodeoxyuridine by deamination. They tested 27 species of 
bacteria for gemcitabine resistance, finding 13 of these bacteria were able to stop gemcitabine from 
inhibiting the growth of RKO human colorectal carcinoma cells. Using human PDAC tissue 
samples, they were also able to detect the presence of bacterial rDNA (ribosomal DNA) and 
compared the number of bacteria found in PDAC tumors to those in a normal pancreas. 76% of 
PDAC samples contained bacteria compared to 15% in normal pancreas samples. The most 
commonly found bacterial species were Gammaproteobacteria.  
  One possible solution to this would be to co-administer antibiotics with cancer therapeutics. 
This was investigated by Geller et al. in which they utilised a colon carcinoma mouse model and 
determined that there was an improved efficacy of gemcitabine when used alongside antibiotics 
(Figure 3) [29]. However, over-use of antibiotics has caused several species of bacteria to become 
multi-drug resistant (MDR) and this resistance is transferable via the super-resistance gene NMD-1 
[74]. One of the possible solutions for this is to administer a bactericidal agent that faces minimal to 
no resistance from bacteria which also have the ability to form the reactive oxygen species that are 
also known to have a bactericidal effect. 
 
Silver nanoparticles 
Colloidal silver is not new. It has been used in multiple sectors for many years. Medically, 
silver nanoparticles (AgNPs) have been impregnated into wound dressings and other topical 
treatments where antimicrobial action is required, as well as being used for surgical coatings, 
dietary supplements, cosmetics, textiles, food packaging, medical implants, and water sterilized 
applications [75]. In 2011, AgNPs accounted for 55.4% of the total nanomaterial-based products on 
the market [76]. 
With a few exceptions, borohydride-mediated reduction has been employed in the majority 
of syntheses of dispersible AgNPs reported [77]. Sodium borohydride (NaBH4) is one of the 
strongest reducing agents for making small size nanoparticles, which facilitates rapid nuclei 
generation, resulting in the formation of monodispersed and uniform sized silver colloids [78]. 
However, NaBH4 is not desirable for making large AgNPs where a slower reaction rate is required 
[79], hence the weaker reducing agent trisodium citrate (TSC) is used. It contributes to the creation 
of relatively large AgNPs, having a wider size distribution [80] and can also result in morphological 
variations of the colloids forming cubes, triangles, rods and spherical nanoparticles [81,82]. Another 
method of AgNP fabrication is via the co-reduction method. Here, the combination of two different 
reductants (NaBH4 and TSC) is employed which results in a more tuneable reaction with a high 
control over the growth of nucleation and nanoparticle formation [83,84]. Using this method, it is 
possible to produce stabilized AgNPs over a wide size range (5–100 nm) [85].  
The characterisation of these materials is relatively simple, with most techniques being both 
well-known and well used in a variety of sectors. Some of the most commonly used techniques 
include UV-vis, dynamic light scattering (DLS), scanning electron microscopy and transmission 
electron microscopy. UV-vis, DLS and both types of electron microscopy give insight into the size 
of the nanoparticles, with electron microscopy also giving insight into the shape of the nanoparticles 
and DLS being able to determine the surface charge and the aggregation of nanoparticles in the 
solution, known as the polydispersity index.  
 Generally, nanoparticles have several properties that make them useful in imaging, drug 
delivery, and creating cancer biomarker profiles of cancerous tumors [86]. AgNPs have several 
applications for cancer, they have been associated with anticancer properties and have been used 
against several cancer types including leukaemia [87], breast cancer [88], lung carcinoma [89], 
hepatocellular carcinoma [90] and glioblastoma [86]. However, there are only limited number of 
studies reported concerning the use of AgNPs in pancreatic cancer therapy. Here, we will discuss 
the progress made to date and possible avenues which could be explored based on the existing 
scientific literature. Table 2 summarised the use of AgNPs for cancer therapy and their stage within 
preclinical testing. 
 
Exploiting inherent cytotoxicity 
AgNPs themselves can be used as a potent anti-cancer agent when administered within a 
certain size range. Hence, there is potential that administration of AgNPs alone into pancreatic 
tumors may result in tumor reduction or retardation. A size dependent cytotoxicity is often 
experienced using AgNPs, where particles below 10 nm exhibit an increased cytotoxic profile 
compared to their larger counterparts. This phenomenon has been observed in a study on pancreatic 
cancer. Zielinska et al. reported the effects of AgNPs on both PANC-1 cancer cells and hTERT 
non-cancerous cell lines, using 2.6 and 18 nm AgNPs. They determined that there was a greater 
cytotoxic effect on the PANC-1 cells than the non-cancerous cells [91]. Additionally, they 
determined that the 2.6 nm AgNPs had a much higher cytotoxicity, around 16 times greater than 
that of the 18 nm AgNPs. The same study also compared using AgNPs to gemcitabine alone, 
determining that gemcitabine was unable to decrease the viability of the PANC-1 cells to the same 
extent as AgNPs. AgNPs were also found to prevent cell proliferation, induce apoptosis and 
necrosis, and cause some changes in the ultrastructure of PANC-1 cells to induce cell death (Figure 
4).  
  There are different methods by which AgNPs act in an anti-cancer manner. Guo et al. 
determined that AgNPs produce reactive oxygen species, reducing the viability of the cells, causing 
DNA damage and inducing apoptosis [87]. This confirmed results from Lim et al. and Arora et al. 
[92,93]. Lim, Gurung and Hande determined that AgNPs have antineoplastic activity, appearing to 
act in a similar manner to many current chemotherapeutics and have been seen to cause cytoskeletal 
deformities [86]. Another study completed by Sriram et al. looked into the effects of AgNPs against 
Dalton’s lymphoma, using a xenografted mouse model [94]. They found that there was a significant 
decrease in tumor volume of 68.5% compared to the control (7.3 mL in the control versus 2.3 mL). 
They also confirmed that AgNPs administered via intraperitoneal injection were able to extend the 
lifespan of the mice to 32 days compared to the control (18 days). 
One explanation for this size dependant cytotoxicity is related to the amount of reactive 
oxygen species generation which is greater with smaller nanoparticles which possess a higher 
surface to volume ratio. Barcińska et al. explored this concept utilising the same cell lines as in 
Zielinska et al., determining that the production of reactive oxygen species in the cancer cell lines 
was double that of the non-cancerous cell lines [95]. Their results in terms of the cytotoxic effects 
of AgNPs on PANC-1 cells confirm those presented by Zielinska et al. As well as this, they 
determined that there was a much higher concentration of nitric oxide present in the PANC-1 cells 
treated with 2.6 nm and 18 nm AgNPs. Both sizes of nanoparticles were able to cause an increase in 
the concentration of nitric oxide present in PANC-1 cells, compared to a control, with the 2.6 nm 
AgNPs causing the greatest increase. The same study also determined that there were significant 
effects on the cell cycle and changes in mitochondrial ultrastructure when utilising AgNPs.  
Another approach reported is to co-administer the AgNPs with a chemotherapy to induce 
synergistic toxicity. Yuan, Peng and Gurunathan utilised AgNPs with gemcitabine to determine if 
combining the two increased the anti-cancer effects against ovarian cancer cells [96]. They initially 
tested AgNPs and gemcitabine individually and determined that a concentration of 25 nM of 
gemcitabine produced a cytotoxic effect and that there was an increase in cytotoxicity at 25 nm of 
AgNPs, both after a 24-hour incubation period. They determined that by combining AgNPs and 
gemcitabine, there was a much more efficient decrease in cell viability compared to the two alone. 
Their results also showed that a lower concentration of AgNPs alongside gemcitabine was able to 
cause the death of cancer cells.  
AgNPs have also been trialled alongside the plant-derived Berberine against human 
squamous carcinoma cells, in this case using the cell line SCC-25 [97]. Dziedzic et al. determined 
that there was a dose-dependent and time-dependent effect on these cells over a 24- and 48-hour 
period using AgNPs alone. These were also shown to cause increase the expression of pro-apoptotic 
Bax at a concentration of 10 μg mL-1, as well as noting significant morphological changes between 
the control and treated cells. For the combination treatment, it was found that there was lower 
cytotoxicity than each component alone. There was mainly Bcl-2 gene expression, with the anti-
apoptotic pathway activated. This would be useful for cells that were not cancerous, as they would 
not be as damaged by the combination treatment as they would the AgNPs alone.   
DNA-dependent protein kinases have been used alongside AgNPs, modifying their 
anticancer ability against glioblastoma (U257) and breast cancer (MCF-7 and MDA-MB-231) cells 
[86]. Lim, Gurung and Hande found that after 48 hours, the shape of the cancerous cells had altered, 
compared to their control counterparts, much like other studies. Further, their report found that 
AgNPs were able to reduce cancerous cell proliferation, cause cell death, a reduction in the 
expression of c-Myc and caused DNA damage.  
There are, as of yet, no clinical trials that have looked into the use of AgNPs as a potential 
treatment for pancreatic cancer, and the majority of the studies listed here are in very early stages. 
There is a clear future for these technologies with their success in these studies, but there is likely to 
be a significant delay before any come into fruition. However, one thing is certain, given their 
known cytotoxicity issues at elevated doses, any new potential therapies will need to be heavily 
scrutinised in terms of accumulation site, residence time, clearance and all associated risks which 
come with these in terms of breakdown and safety before clinical translation could be realised. 
 
Exploiting inherent antimicrobial nature of silver nanoparticles  
As greater understanding of the tumor microenvironment is elucidated, these environments 
are being increasingly implicated in the clinical failure of current chemotherapeutics. For instance, 
the recent study by Geller et al. published in Science described how colorectal tumors were 
becoming resistant to gemcitabine due to the presence of Gammaproteobacteria and subsequent 
expression of cytidine deaminase within the tumor site, which converts gemcitabine into an inactive 
form [29]. With this knowledge, it may be possible to improve the efficacy of existing therapies by 
addressing the bacteria residing in the microenvironment. One of the most well-known materials 
with antibacterial properties is silver. Silver itself has been used in therapies since ancient times, 
and is used in various applications, including films and dressings [98]. 
 Silver ions inhibit bacteria using several mechanisms, including inhibition of respiratory 
chain enzymes, interfering with membrane permeability [78] and affecting DNA replication [100] 
(Figure 5). The way in which silver ions are distributed differs, with 60% entering the cell and 40% 
binding to the surface of the bacteria [98].  It has been suggested by Marini et al. that AgNPs have a 
similar mode of action to silver nitrate, releasing silver ions [100]. A study by Shrivastava et al. 
determined that the main pathway by which AgNPs exhibit antibacterial activity was by attaching to 
and then passing through the bacterium’s cell wall [101].   
  AgNPs possess excellent antimicrobial properties as well as being able to affect other 
microbes, including protozoa and fungi [102,103]. Several studies have looked into the use of 
AgNPs on various viruses including hepatitis B [104], influenza virus [105] and HIV-1 [106, 107], 
all of which found that AgNPs had some effect.  As well as these, there have been studies into the 
use of AgNPs against fungi. A study by Kim et al. looked into the effects of AgNPs on several 
different types of fungi that were pathogenic towards plants [108]. These included A. alternata, B. 
cinereal and F. oxysporum. They found that when AgNPs with a relatively low concentration were 
effective against the fungi tested, but these were only tested in vitro.   
 The physical properties of AgNPs have an impact on their antimicrobial activity. One of 
these important properties is their size. Studies by both Martinéz-Castañón et al. and Morones et al. 
found that smaller AgNPs possess greater bactericidal activity [109,110].  
    There have been several studies that have examined and utilised the antibacterial properties 
of AgNPs.  Lok et al. synthesised both reduced and oxidised AgNPs and tested them for their 
antimicrobial activity against E. coli [99]. They noted that oxidised AgNPs had better antibacterial 
properties, linked to their size and shape. Shrivastava et al. tested the antibacterial effects of AgNPs 
against E. coli, S. aureus, ampicillin-resistant E. coli and an MDR strain of S. typhus [101]. Their 
study determined that using increased concentrations of AgNPs enhanced their effect, with a 
concentration of 25 μg mL-1 inhibiting the growth of all of the bacterial strains listed. Martinéz-
Castañón et al. completed a study looking into how different sizes of AgNPs impacted their 
antimicrobial effect [109]. They generated AgNPs that were 7, 29 and 89 nm. The largest size of 
AgNPs also exhibited a slightly different shape, being less spherical than the two smaller 
counterparts. Overall, they determined that the smaller size of AgNPs presented with the greatest 
antibacterial effect against both E. coli and S. aureus. 
  As well as nanoparticles possessing their own antimicrobial activity, several studies, 
including those by Fayaz et al. and Shahverdi et al. have investigated the use of antibiotics 
alongside AgNPs [111], including attaching antibiotics to the surface of AgNPs [112]. Fayaz et al. 
tested biogenically synthesised AgNPs with antibiotics against four different species of bacteria, 
including two strains of gram-negative (E. coli and S. typhi) and two strains of gram-positive (S. 
aureus and M. luteus) bacteria. They discovered that the antimicrobial properties of all the 
antibiotics they utilised were increased when co-administered with AgNPs. Shahverdi et al. 
determined that the nanoparticles were more effective against S. aureus than against E. coli. Brown 
et al. used AgNPs to carry ampicillin, aiming to improve the efficacy of the drug [113]. The data 
showed that the AgNPs which were functionalised with ampicillin were effective against a broad-
spectrum of bacteria (both Gram-negative and Gram-positive) and excitingly, they possessed the 
ability to subvert the antibiotic resistance mechanisms in multiple-drug-resistant bacteria. 
  There have also been studies looking into the combination of two different antimicrobial 
agents, one of which being AgNPs, and determining if this produces an increased or synergistic 
antibacterial effect. Chen et al. developed polymer colloids which were coated with AgNPs [114]. 
These were tested against E. coli and were found to completely inhibit its growth, similar to the 
results found in the study of Lok et al. [99]. They also determined that these effects were dependent 
on both the size and dose used, with the lower concentration range of 1 to 10 μg mL-1 having little 
effect [114].  
 Shankar, Wang and Rhim tested the release of silver ions from a variety of materials 
including AgNPs, within alginate-based composite films in order to allow for a steady release of 
silver over time [115]. They synthesised AgNPs using citrate as the reducing agent and also used 
laser ablated AgNPs and tested them against E. coli and L. monocytogenes. It was determined that 
the reduced AgNPs had potent antibacterial activity whereas the laser ablated AgNPs had little to no 
effect on bacteria. There was also a greater effect on the gram-negative E. coli than the gram-
positive L. monocytogenes. Similar to the study by Shankar, Wang and Rhim, Acharya et al. 
developed AgNPs alongside alginate and gelatin hydrogel films [116]. They were tested against 
several bacterial strains, including S. typhi, P. aeruginosa, E. coli and S. aureus and found that the 
Gram-negative bacteria strains were more affected by the composites than the Gram-positive 
bacteria.  
  Kong and Jang synthesised AgNP-containing poly(methyl methacrylate) nanofibers for 
antibacterial purposes, in order to allow for a steady release of silver over time, alike the work 
reported by Shankar, Wang and Rhim [115,117]. They tested their nanofibers against E. coli and S. 
aureus and determined that the antibacterial activity of the nanofibers was superior to those of both 
silver nitrate and silver sulfadiazine alone.  
  Overall, the antibacterial properties of AgNPs have been well tested, with various papers 
using AgNPs alone and others using AgNPs alongside other materials in order to allow for 
controlled release. The majority of studies that utilised a different species of bacteria determined 
that there was a difference in the efficacy of AgNPs on Gram-positive and Gram-negative bacteria, 
with Gram-negative bacteria generally being better affected. Therefore, we propose that this is one 
major area for consideration in improving drug efficacy for gemcitabine treatment. The AgNPs will 
selectively reduce bacterial presence, hence allowing the drug to carry out its well-established 
function. Additionally, the AgNPs may act as a drug carrier to bring the gemcitabine to its site of 
action. This concept will be further addressed in the drug delivery section below. 
Drug Targeting and Delivery 
The surface of AgNPs is well suited to modification both electrostatically and covalently. A 
net negative zeta potential renders cationic charge-charge van der Waals interactions as one 
possibility for attachment of drugs or other molecules of interest. Additionally, covalent conjugation 
of molecules onto the surface of AgNPs is easily achieved using dative covalent bonding with thiol 
or disulphide residues. 
   There is great debate within the nanomedicine community regarding the passive targeting 
ability of nano-carriers via enhanced permeability and retention (EPR) effect in pancreatic tumors. 
Multiple studies have shown increased drug efficacy after either conjugation onto the surface of, or 
encapsulation within the core of, nanoparticles [118]. However, this increase in efficacy may solely 
be down to the prolonged circulation times of these nanoparticles and not due to EPR effect given 
the highly dense stroma surrounding these problematic tumors. To compensate for this lack of 
clarity, the use of targeting moieties is routinely used in nanomedicine design for pancreatic cancer 
therapy [119]. These include the use of folic acid [120], peptides [121] and specific antibodies 
[122]. These moieties undergo active transport internalisation processes (Figure 6) which help to 
preferentially traffic the therapies into the cancerous cells which allow for deeper tumor penetration 
whilst evading healthy tissue and indeed macrophage clearance in the bloodstream. 
 A wealth of data has been generated using gold nanoparticles (AuNPs) for pancreatic cancer 
drug delivery [123-125]. Gold coated iron oxide have been shown to enhance activity of 
gemcitabine through controlling its release with laser initiated heat resulting in tumour reduction in 
pancreatic xenografts compared with the free drug (Figure 7) [124]. It is postulated that these could 
be replicated using AgNPs with very similar mechanism of action, with the added benefit of 
antimicrobial activity. As long as any inherent toxicity is addressed in terms of appropriate particle 
size and surface modification with polymers or other biocompatible moieties, issues such as toxicity 
on administration and accumulation can be addressed. The use of AgNPs for targeted drug delivery 
has already been shown in other cancers. Folic acid conjugated AgNPs were fabricated and 
anticancer drug doxorubicin was electrostatically attached onto their surface [126]. The study 
showed that drug release occurred into the cytoplasm after 4 hours with significant cell death 
observed after 8 hours. 
Another study reported that galactomannan conjugated AgNPs possess enhanced anticancer 
action in adenocarcinoma alveolar basal (A549), colorectal carcinoma (HCT116) and hepatocellular 
carcinoma (HepG2) cancer cell lines, compared against a control of mouse fibroblast cell lines 
(3T3-L1), displaying a lower level of toxicity towards normal cells [127].  
It is envisaged that data reported to date in these other cancer types will spark the interest of 
pancreatic cancer researchers and subsequent studies will commence in this area.   
   
Thermal therapy 
  Tumor ablation has been tested for use against several different types of cancer, including 
prostate [128] kidney, bone and lung cancers [129]. There are several types of ablation that have 
been tested for use as therapeutics, including radiofrequency ablation [130], cryoablation [131] and 
focal laser ablation [132]. Like AuNPs, AgNPs possess a surface plasmon resonance wavelength at 
which irradiated light becomes scattered and absorbed. The absorption rapidly transfers light into 
thermal energy allowing the nanoparticles to act as localised heaters which can be used for both 
ablation and heat mediated drug release. Although the absorption is reduced in AgNPs compared 
with AuNPs, theory suggests that the heating potential of AgNPs should be sufficient to generate 
thermal increases required for irreversible cell damage. As of yet no studies have been reported in 
the pancreatic field, however, with all the benefits of using AgNPs outlined above, it is postulated 
that this will be a further area of research interest with a high likelihood of success. Additionally, 
these platforms may be tailored, as AuNPs have been in order to act as a triggered stage for drug 
release using light and/or thermal energy [133]. 
   
Radiation enhancers   
Radiation therapy is common in patients with pancreatic cancer. AuNPs have already been shown 
to work as radiation sensitizers in breast cancer therapy [134] [135], hence this application may be 
another opportunity to harness the power of AgNPs. Swanner et al. reported that AgNPs were 
selectively cytotoxic towards triple negative cells at doses which had minimal effect on non-tumor 
cells [136]. Here the study confirmed that AgNPs induced more DNA and oxidative damage in the 
cancerous cells which is responsible for their ultimate mortality. They used these AgNPs in 
combination with infrared radiation at doses of 0–4 Gy (dose rate of 2.39 Gy/min) both in vitro and 
in vivo. Excitingly, the combination therapy resulted in a dose-enhancement effect in the triple 
negative breast cancer and was found to be nontoxic to healthy tissue. Similarly, Lu et al.  
demonstrated that protein coated AgNPs enhanced X-ray radiation dosages to a different strain of 
breast cancer cells (231) in vitro compared to the radiation alone [137]. Liu et al. found that AgNPs 
actually outperformed AuNPs in their radiosensitizing properties in U251 cells and in an 
intracranial mouse glioma model [138]. This exciting finding gives much promise to the future of 
AgNPs within this arena. Currently, the use of AuNPs for cancer therapy is a huge area of 
investigation across multiple cancer types. Liu postulated that the increased enhancement ability 
possessed by the AgNPs compared to that of the AuNPs was due to the increased pro-apoptotic 
effects. Another example of how the many attributes of silver, if harnessed correctly, may lead to an 
upsurge in scientific investigation over the coming decade, particularly for difficult diseases such as 
pancreatic cancer. 
 
Conclusion  
The number of articles on silver nanoparticles in pancreatic cancer therapy is growing. The recent 
review chapter written by Skonieczna and Hudy shows the increasing popularity of silver 
nanoparticles for their various properties, including antimicrobial and anticancer properties [139]. 
Increased interest in these systems has been realised due to their unique nanoscale properties. The 
combination of ease of manufacture, tailoring ability, relative cost, antimicrobial properties tuneable 
optical and toxicological profiles renders these particles interesting platforms for pancreatic cancer 
therapy. Since these nanoparticles are currently at the early stages of testing and fabrication, there 
would need to be careful regulation of AgNPs before administering any of the listed treatments to 
patients, especially due to the fact that there is evidence of AgNPs causing DNA damage to normal 
human cell lines [140]. Possible “interfering factors” include the shape, size, stability, 
pharmacokinetics and accumulation of these nanoparticles. As well as this, there would need to be 
an investigation into any possible effects that this could have on the environment, as silver is known 
to be toxic to aquatic life.  
 As more investment in this under-represented cancer is realised, so too will the full 
potential of colloidal silver in its treatment. They say that every cloud has a silver lining, in this case 
we hope that the silver lining of tumors will lead to increased patient survival and long-term quality 
of life.  
Corresponding Author 
*Clare Hoskins, Tel: +441782 734799; email: c.hoskins@keele.ac.uk 
Author Contributions 
RF, MA and CH wrote the manuscript. AC provided the figures. CH supervised and approved the 
content. All authors have given approval to the final version of the manuscript. 
References 
1. F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, A. Jemal, Global Cancer 
Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers 
in 185 Countries, CA Cancer J. Clin., 2018, 0, 1-31 
2. R. L. Siegel, K. D. Miller and A. Jemal, Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68, 
7-30 
3. J. Kleef, M. Korc, M. Apte, C. La Vecchia, C. D. Johnson, A. V. Biankin, R. E. Neale, M. 
Tempero, D. A. Tuveson, R. H. Hruban and J. P. Neoptolemos., Pancreatic Cancer., Nat. Rev. 
Dis. Primers, 2016, 2, 16022  
4. L. Zou, R. Zhong, N. Shen, W. Chen, B, Zhu, J. Ke, X. Lu, T. Zhang, J. Lou, Z. Wang, L. Liu, 
L. Qi and X. Miao, Non-Linear Dose–Response Relationship Between Cigarette Smoking and 
Pancreatic Cancer Risk: Evidence from a Meta-Analysis of 42 Observational Studies  Eur. J. 
Cancer, 2014, 50, 193–203  
5. S. C. Larsson, N. Orsini and A. Wolk, Body Mass Index and Pancreatic Cancer Risk: A Meta-
Analysis of Prospective Studies. Int. J. Cancer, 2007, 120, 1993–98 
6. S. Chand, K O’Hayer, F. F. Blanco, J. M. Winter and J. R. Brody, The Landscape of Pancreatic 
Cancer Therapeutic Mechanisms, Int. J. Biol. Sci., 2016, 12, 237-282  
7. I. Tramacere, L. Scotti, M. Jenab, V. Bagnardi, R. Bellocco, M. Rota, G. Corrao, F. Bravi, P. 
Boffetta, and C. La Vecchia. Alcohol Drinking and Pancreatic Cancer Risk: A Meta-Analysis of 
the Dose-Risk Relation. Int. J. Cancer, 2010, 126, 1474–86. 
8.  D. S. Michaud, A. Vrieling, L. Jiao, J. B. Mendelsohn, E. Steplowski, S. M. Lynch, J. 
Wactawski-Wende, A. A. Arslan, H. B. Bueno-de-Mesquita, C. S. Fuchs, M. Gross, K. 
Helzlsouer, E. J. Jacobs, A. LaCroix, G. Petersen, W. Zheng, N. Allen, L. Ammundadottir, M. 
M. Bergmann, P. Boffetta, J. E. Buring, F. Canzian, S. J. Chanock, F. Clavel-Chapelon, S. 
Clipp, M. S. Freiberg, J. M. Gaziano, E. L. Giovannucci, S. Hankinson, P. Hartge, R. N. 
Hoover, F. A. Hubbell, D. J. Hunter, A Hutchinson, K. Jacobs, C. Kooperberg, P. Kraft, J. 
Manjer, C. Navarro, P. H. M. Peeters, X. Shu, V. Stevens, G. Thomas, A. Tjønneland, G. S. 
Tobias, D. Trichopoulos, R. Tumino, P. Vineis, J. Virtamo, R. Wallace, B. M. Wolpin, K. Yu, 
A. Zeleniuch-Jacquotte, and R. Z. Stolzenberg-Solomon, Alcohol Intake and Pancreatic Cancer: 
A Pooled Analysis from the Pancreatic Cancer Cohort Consortium (PanScan), Cancer Causes 
Control, 2010, 21, 1213-–25. 
9. L. Jiao, A. Berrington de Gonzalez, P. Hartge, R. M. Pfeiffer, Y. Park, D. M. Freedman, M. H. 
Gail, M. C. R. Alavanja, D. Albanes, L. E. Beane Freeman, W. Chow, W. Huang, R. B. Hayes, 
J. A. Hoppin, B. Ji, M. F. Leitzmann, M. S. Linet, C. L. Meinhold, C. Schairer, A. Schatzkin, J. 
Virtamo, S. J. Weinstein, W. Zheng, and R. Z. Stolzenberg-Solomon. Body Mass Index, Effect 
Modifiers, and Risk of Pancreatic Cancer: A Pooled Study of Seven Prospective Cohorts, 
Cancer Causes Control, 2010, 21, 1305–1314  
10. Q. Ben, M. Xu, X. Ning. J. Liu, S. Hong. W. Huang, H. Zhang, and Z. Li, Diabetes Mellitus and 
Risk of Pancreatic Cancer: A meta-analysis of cohort studies. Eur J Cancer, 2011, 47, 1928–37. 
11. J. Starup-Linde, Ø. Karlstad, S. Aistrup Eriksen, P. Vestergaard, H. K. Bronsveld, F. de Vries, 
M. Andersen, A. Auvinen, J. Haukka, V. Hjellvik, M. T. Bazelier, A. de Boer, K. Furu, and M. 
L. De Bruin, CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes 
Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a 
Meta-Analysis. Curr. Drug Saf., 2013, 8, 296–332. 
12. J. Permuth-Wey and K. M. Egan, Family History is a Significant Risk Factor for Pancreatic 
Cancer: Results from a Systematic Review and Meta-Analysis. Fam. Cancer, 2009, 8, 109–117 
13. E. J. Jacobs S. J Chanock, C. S. Fuchs, A. Lacroix, R. R. McWilliams, E. Steplowski, R. Z. 
Stolzenberg-Solomon, A. A. Arslan, H. B. Bueno-de-Mesquita, M. Gross, K. Helzlsouer, G. 
Petersen, W. Zheng, I. Agalliu, N. E. Allen, L. Amundadottir, M. C. Boutron-Ruault, J. E. 
Buring, F. Canzian, S. Clipp, M. Dorronsoro, J. M. Gaziano, E. L. Giovannucci, S. E. 
Hankinson, P. Hartge, R. N. Hoover, D. J. Hunter, K. B. Jacobs, M. Jenab, P. Kraft, C. 
Kooperberg, S. M. Lynch, M. Sund, J. B. Mendelsohn, T. Mouw, C. C. Newton, K. Overvad, D. 
Palli, P. H. Peeters, A. Rajkovic, X. O. Shu, G. Thomas, G. S. Tobias, D. Trichopoulos, J. 
Virtamo, J. Wactawski-Wende, B. M. Wolpin, K. Yu, and A. Zeleniuch-Jacquotte. Family 
History of Cancer and Risk of Pancreatic Cancer: A Pooled Analysis from the Pancreatic 
Cancer Cohort Consortium (PanScan). Int. J. Cancer, 2010, 127, 1421–1428  
14. S. Yachida, S. Jones, I. Bozic, T. Antal, R. Leary, B. Fu, M. Kamiyama, R. H. Hruban, J. R. 
Eshleman, M. A. Nowak, V. E. Velculescu, K. W. Kinzler, B. Vogelstein & C. A. Iacobuzio-
Donahue, Distant Metastasis Occurs Late During the Genetic Evolution of Pancreatic Cancer, 
Nature, 2010, 467, 1114-1119 
15. R. A. Burrell, N. McGranahan, J. Bartek and C. Swanton, The Causes and Consequences of 
Genetic Heterogeneity in Cancer Evolution, Nature, 2013, 501, 338-345 
16. E. S. Lee and J. M. Lee, Imaging Diagnosis of Pancreatic Cancer: a state-of-the-art review. 
World J. Gastroenterol., 2014, 20, 7864-7877 
17. M. Chiaravalli, M. Reni and E. M. O’Reilly, Pancreatic Ductal Adenocarcinoma: State-of-the-
Art 2017 and New Therapeutic Strategies, Cancer Treatment Reviews, 2017, 60, 32-43 
18. M. T Saung and L. Zhang, Current Standards of Chemotherapy for Pancreatic Cancer, Clin. 
Therap., 2017, 39, 2125-2134  
19. M. Hidalgo, S. Cascinu, J. Kleef, R. Labianca, J. M. Löhr, J. Neoptolemos, F. X. real, J. L. Van 
Laethem, and V. Heinemann. Addressing the Challenges of Pancreatic Cancer: Future 
Directions for Improving Outcomes. Pancreatology, 2015, 15, 8-18  
20. L. Rahib, B. D. Smith, R. Aizenberg, A.B. Rosenzweig, J. M. Fleshman, and L. M. Matrisian.  
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, 
and Pancreas Cancers in the United States. Cancer Res., 2014, 74, 2913-2921 
21. H. Matthaei, R. D. Schulick, R. H. Hruban and A. Maitra, Cystic Precursors to Invasive 
Pancreatic Cancer. Nat. Rev. Gastroenterol. Hepatol., 2011, 8, 141-150 
22. J. Wu, Y. Jiao, M. Dal Molin, A. Maitra, R. F. de Wilde, L. D. Wood, J. R. Eshleman, M. G. 
Goggins, C. L. Wolfgang, M. I. Canto, R. D. Schulick, B. H. Edil, M. A. Choti, V. Adsay, D. S. 
Klimstra, G. Johan A. Offerhaus, A. P. Klein, L. Kopelovich, H. Carter, R. Karchin, P. J. Allen, 
C. M. Schmidt, Y. Naito, L. A. Diaz Jr., K. W. Kinzler, N. Papadopoulos, R. H. Hruban, and B. 
Vogelstein. Whole-Exome Sequencing of Neoplastic Cysts of the Pancreas Reveals Recurrent 
Mutations in Components of Ubiquitin-Dependent Pathways. Proc. Natl. Acad. Sci. USA, 2011, 
108, 21188-21193 
23. A. M. Macgregor-Das and C. A. Iacobuzio-Donahue, Molecular Pathways in Pancreatic 
Carcinogenesis. J. Surg. Oncol., 2013, 107, 8-14 
24. R. H. Hruban, N. Volkan Adsay, J. Albores–Saavedra, C. Compton, E. S. Garrett, S. N. 
Goodman, S. E. Kern, D. S. Klimstra, G. Klöppel, D. S. Longnecker, J. Lüttges, and G. Johan 
A. Offerhaus, Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification 
System for Pancreatic Duct Lesion. Am. J. Surg. Pathol., 2001, 25, 579-586  
25. D. X. Nguyen and J. Massagué, Genetic Determinants of Cancer Metastasis, Nat. Rev. Genet., 
2007, 8, 341-352  
26. H. Ying, P. Dey, W. Yao, A. C. Kimmelman, G. F. Draetta, A. Maitra, and R. A. DePinho. 
Genetics and Biology of Pancreatic Ductal Adenocarcinoma. Genes Dev., 2016, 15, 355-385  
27. I. Garrido-Laguna and M. Hidalgo, Pancreatic Cancer: From State-of-the-Art Treatments to 
Promising Novel Therapies. Nat. Rev. Clin. Oncol., 2015, 12, 319-34 
28. H. A Burris 3rd, M J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg, M. R. Modiano M. 
C. Cripps, R. K. Portenoy, A. M. Storniolo, P. Tarassoff, R. Nelson, F. A. Dorr, C. D. Stephens, 
and D. D. Von Hoff, Improvements in Survival and Clinical Benefit with Gemcitabine as First-
Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial., J. Clin. 
Oncol., 1997, 15, 2403-2413  
29. L. T. Geller, M. Barzily-Rokni, T. Danino, O. H. Jonas, N. Shental, D. Nejman, N. Gavert, Y. 
Zwang, Z. A. Cooper, K. Shee, C. A. Thaiss, A. Reuben, J. Livny, R. Avraham, D. T. Frederick, 
M. Ligorio, K. Chatman, S. E. Johnston, C. M. Mosher, A. Brandis, G. Fuks, C. Gurbatri, V. 
Gopalakrishnan, M. Kim, M. W. Hurd, M. Katz, J. Fleming, A. Maitra, D. A. Smith, M. Skalak, 
J. Bu, M. Michaud, S. A. Trauger, I. Barshack, T. Golan, J. Sandbank, K. T. Flaherty, A. 
Mandinova, W. S. Garrett, S. P. Thayer, C. R. Ferrone, C. Huttenhower, S. N. Bhatia, D. 
Gevers, J. A. Wargo, T. R. Golub, and R. Straussman. Potential Role of Intratumor Bacteria in 
Mediating Tumor Resistance to the Chemotherapeutic Drug Gemcitabine. Science, 2017, 357, 
1156-1160  
30. M. Reni, S. Cordio, C. Milandri, P. Passoni, E. Bonetto, C. Oliani, G. Luppi, R. Nicoletti, L. 
Galli, R. Bordonaro, A. Passardi, A. Zerbi, G. Balzano, L. Aldrighetti, Prof. C. Staudacher, E. 
Villa and Prof V. Di Carlo. Gemcitabine versus Cisplatin, Epirubicin, Fluorouracil, and 
Gemcitabine in Advanced Pancreatic Cancer: A Randomised Controlled Multicentre Phase III 
Trial Lancet Oncol., 2005, 6, 369-376 
31. D. Cunningham, I. Chau, D. D. Stocken, J. W. Valle, D. Smith, W. Steward, P. G. Harper, J. 
Dunn, C. Tudur-Smith, J. West, S. Falk, A. Crellin, F. Adab, J. Thompson, P. Leonard, J. 
Ostrowski, M. Eatock, W. Scheithauer, R. Herrmann, J. P. Neoptolemos. Phase III Randomized 
Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced 
Pancreatic Cancer. J. Clin. Oncol., 2009, 27, 5513–5518 
32. S. Gourgou-Bourgade, C. Bascoul-Mollevi, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, 
Y. Bécouarn, A. Adenis, J. L. Raoul, V. Boige, J. Bérille and T. Conroy. Impact of 
FOLFIRINOX Compared with Gemcitabine on Quality of Life in Patients with Metastatic 
Pancreatic Cancer: Results from the PRODIGE 4/ACCORD 11 Randomized Trial. J. Clin. 
Oncol., 2013, 31, 23-29 
33. T. Conroy, F. Desseigne, M. Ychou, and O. Bouché, FOLFIRINOX versus Gemcitabine for 
Metastatic Pancreatic Cancer. N. Engl. J. Med., 2011, 364, 1817-1825 
34. D. D. von Hoff, T. Ervin, F. P. Arena, E. G. Chiorean, J. Infante, M. Moore, T. Seay, S. A. 
Tjulandin, M. Hidalgo, D. Goldstein, E. Van Cutsem, X. Wei, J. Iglesias and M. F. Renschler, 
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N. Engl. J. Med., 
2013, 369, 1691-1703 
35.    M. Reni, S. Zanon, G. Balzano, P. Passoni, C. Pircher, M. Chiaravalli, C. Fugazza, D. 
Ceraulo, R. Nicoletti, P. G. Arcidiacono, M. Macchini, U. Peretti, R. Castoldi, C. Doglioni, M. 
Falconi, S. Partelli and L. Gianni, A Randomised Phase 2 Trial of nab-Paclitaxel plus 
Gemcitabine with or without Capecitabine and Cisplatin in Locally Advanced or Borderline 
Resectable Pancreatic Adenocarcinoma, Eur. J. Cancer, 2018, 102, 95-102 
36. A. Stathis and M. J. Moore, Advanced Pancreatic Carcinoma: Current Treatment and Future 
Challenges. Nat. Rev. Clin. Oncol., 2010, 7, 163-72 
37. T. Conroy, J. B. Bachet, A. Auav, F. Huguet, A. Lambert, C. Caramella, R. Maréchal, J. L. Van 
Laethem and M. Ducreux, Current Standards and New Innovative Approaches for Treatment of 
Pancreatic Cancer. Eur. J. Cancer, 2016, 57, 10-22M  
38. Ducreux, E. Mitry, M. Ould-Kaci, V. Boige, J. F. Seitz, R. Bugat, J. L. Breau, O. Bouché, P. L. 
Etienne, J. M. Tigaud, F. Morvan, E. Cvitkovic and P. Rougier. Randomized phase II study 
Evaluating Oxaliplatin alone, Oxaliplatin combined with Infusional 5-FU, and Infusional 5-FU 
alone in Advanced Pancreatic Carcinoma Patients. Ann Oncol., 2004, 15, 467-73 
39. J. P. Neoptolemos, D. D. Stocken, H. Friess, C. Bassi, J. A. Dunn, H. Hickey, H. Berger, L. 
Fernandez-Cruz, C. Dervenis, F. Lacaine, M. Falconi, P. Pederzoli, A. Pap, D. Spooner, D. J. 
Kerr and M. W. Büchler, A Randomized Trial of Chemoradiotherapy and Chemotherapy after 
Resection of Pancreatic Cancer. N. Engl. J. Med., 2004, 350, 1200e10  
40. H.Y. Tanaka, M.R. Kano, Stromal Barriers to Nanomedicine Penetration in the Pancreatic 
Tumor Microenvironment, Cancer Sci., 2018, 109, 2085-2092 
41. F. Klemm and J. A. Joyce, Microenvironmental Regulation of Therapeutic Response in Cancer. 
Trends Cell Biol., 2015, 25(4), 198–213S. L. Topalian et al., N. Engl. J. Med., 2012, 366, 2443–
2454 
42. S. L. Topalian, F. S Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. 
Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. 
Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L.Chen, W. H. Sharfman, R. A. Anders, J. M. 
Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. 
Kollia, A. Gupta, J. M. Wigginton, and M. Sznol, Safety, Activity, and Immune Correlates of 
Anti–PD-1 Antibody in Cancer, N. Engl. J. Med., 2012, 366, 2443–2454 
43. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. Rong Qian, J. Du, A. Davis, M. M. 
Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. 
Lo, K. T. Flaherty, S. Ogino, J. A. Wargo & T. R. Golub, Tumor Micro-Environment Elicits 
Innate Resistance to RAF Inhibitors through HGF Secretion. Nature., 2012, 487, 500–504 
44. C. Li, D. G. Heidt, P. Dalerba, C. F. Burant, L. Zhang, V. Adsay, M. Wicha, M. F. Clarke and 
D. M. Simeone, Identification of Pancreatic Cancer Stem Cells, Cancer Res., 2007, 67, 1030-
1037 
45. P. C. Hermann, S. L. Huber, T. Herrier, A. Aicher, J. W. Ellwart, M. Guba, C. J. Bruns, and C. 
Heeschen, Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic 
Activity in Human Pancreatic Cancer, Cell Stem Cell, 2007, 1, 313-323 
46. R. F. Hwang, T. Moore, T. Arumugam, V. Ramahandran, K. D. Amos, A. Rivera, B. Ji, D. B. 
Evans, and C. D. Logsdon, Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor 
Progression, Cancer Res., 2008, 68, 918-926 
47. A. Mantovani and A. Sica, Macrophages, Innate Immunity and Cancer: Balance, Tolerance, and 
Diversity, Curr. Op. Immunol., 2010, 22, 231-237 
48. A. Mantovani, P. Allavena, A. Sica and F. Balkwill, Cancer-Related Inflammation. Nature, 
2008, 454, 436-444 
49. J. R. Sierra, S. Corso, L. Caione, V. Cepero, P. Conrotto, A. Cignetti, W. Piacibello, A. 
Kumanogoh, H. Kitutani, P. M. Comoglio, L. Tamagnone and S. Giordano, Tumor 
Angiogenesis and Progression are Enhanced by Sema4D Produced by Tumor-Associated 
Macrophages, J Exp Med, 2008, 205, 1673-1685 
50. S. Loges, T. Schmidt, M. Tjwa, K. van Geyte, D. Lievens, E. Lutgens, D. Vanhoutte, D. Borgel, 
S. Paisance, M. Hoylaerts, A. Luttun, M. Dewerchin, B. Jonckx and P. Carmeliet, Malignant 
Cells Fuel Tumor Growth by Educating Infiltrating Leukocytes to Produce the Mitogen Gas6. 
Blood, 2010, 115, 2264-2273 
51. T. Hagemann, J. Wilson, F. Burke, H. Kulbe, N. F. Li, A. Plüddemann, K. Charles, S. Gordon 
and F. R. Balkwill, Ovarian Cancer Cells Polarize Macrophages Toward a Tumor-Associated 
Phenotype, J. Immunol., 2006, 176, 5023-5032 
52. S. Kim, H. Takahashi, W. W. Lin, P. Descargues, S. Grivennikov, Y. Kim, J. L. Luo and M. 
Karin, Carcinoma-Produced Factors Activate Myeloid Cells through TLR2 to Stimulate 
Metastasis, Nature, 2009, 457, 102-106 
53. Z. Xu, A. Vonlaufen, P. A. Phillips, E. Fiala-Beer, X. Zhang, L. Yang, A. V. Biankin, D. 
Goldstein, R. C. Pirola, J. S. Wilson and M. V. Apte, Role of Pancreatic Stellate Cells in 
Pancreatic Cancer Metastasis, American J. of Pathol., 2010, 177, 2585-2596 
54. N. Erez, M. Truitt, P. Olson, S. T. Arron and D. Hanahan, Cancer-Associated Fibroblasts Are 
Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-
kappaB-Dependent Manner, Cancer Cell, 2010, 17, 135-147 
55. K. E. de Visser, L. V. Korets and L. M. Coussens, De Novo Carcinogenesis Promoted by 
Chronic Inflammation is B Lymphocyte Dependent, Cancer Cell, 2005, 7, 411–423  
56. R. V. Iozzo, Series Introduction: Heparan Sulfate Proteoglycans: Intricate Molecules with 
Intriguing Functions, J. Clin. Invest., 2001, 108, 165-167 
57. R. V. Iozzo, Basement Membrane Proteoglycans: From Cellar to Ceiling, Nature Rev. Mol. Cell 
Biol., 2005, 6, 646-656 
58. R. V. Iozzo, J. J. Zoeller and A. Nyström, Basement Membrane Proteoglycans: Modulators Par 
Excellence of Cancer Growth and Angiogenesis, Mol. Cells, 2009, 27, 503-513 
59. R. D. Sanderson and Y. Yang, Syndecan-1: A Dynamic Regulator of the Myeloma 
Microenvironment, Clin. Exp. Metastasis, 2008, 25, 149-159  
60. J. Filmus and S. B. Selleck, Glypicans: Proteoglycans with a Surprise, J. Clin. Invest., 2001, 
108, 497-501 
61. R. V. Iozzo and L. Schaefer, Proteoglycans in Health and Disease: Novel Regulatory Signaling 
Mechanisms Evoked by the Small Leucine-Rich Proteoglycans, FEBS J., 2010, 277, 3864-3875 
62. A. K. Witkiewicz, E. A. McMillan, U. Balaji, G. Baek, W. C. Lin, J. Mansour, M. Mollaee, K. 
U. Wagner, P. Koduru, A. Yopp, M. A. Choti, C. J. Yeo, P. McCue, M. A. White & E. S. 
Knudsen, Whole-Exome Sequencing of Pancreatic Cancer Defines Genetic Diversity and 
Therapeutic Targets, Nat Commun., 2015, 6, 6744(1-11) 
63. P. J. Grippo and E. P. Sandgren, Acinar‐to‐Ductal Metaplasia Accompanies c‐myc‐Induced 
Exocrine Pancreatic Cancer Progression in Transgenic Rodents, Int J Cancer, 2012, 131, 1243-
1248 
64. W. C. Lin, N. Rajbhandari, C. Liu, K. Sakamoto, Q. Zhang, A. A. Triplet, S. K. Batra, R. 
Opavsky, D. W. Felsher, D. J. DiMaio, M. A. Hollingsworth, J. P. Morris, M. Hebrok, A. K. 
Witkiewicz, J. R. Brody, H. Rui and K. U. Wagner, Dormant Cancer Cells Contribute to 
Residual Disease in a Model of Reversible Pancreatic Cancer, Cancer Res., 2013, 73, 1821-
1830 
65. P. K. Mazur, H. Einwächtera, M. Leea, B. Siposb, H. Nakhaic, R. Radd, U. Zimber-Stroble, L. 
J. Stroble, F. Radtkef, G. Klöppelg, R. M. Schmida, and J. T. Sivekea, Notch2 is Required for 
Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Ductal 
Adenocarcinoma, Proc. Natl. Acad. Sci. USA., 2010, 107, 13438–13443. 
66. M. Erkan, S. Hausmann, C. W. Michalski, A. A. Fingerle, M. Dobritz, J. Kleeff, and H. Friess, 
The Role of Stroma in Pancreatic Cancer: Diagnostic and Therapeutic Implications, Nat Rev. 
Gastroenterol. Hepatol., 2012, 9, 454-467 
67. M. V. Apte, S. Park, P. A. Phillips, N. Santucci, D. Goldstein, R. K. Kumar, G. A. Ramm, M. 
Buchler, H. Friess, J. A. McCarroll, G. Keogh, N. Merrett, R. Pirola and J. S. Wilson, 
Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells, Pancreas, 2004, 
29, 179–187 
68. M. V. Apte, P. S. Haber, T. L. Applegate, I. D. Norton, G. W. McCaughan, M. A. Korsten, R. 
C. Pirola, and J. S. Wilson, Periacinar Stellate Shaped Cells in Rat Pancreas: Identification, 
Isolation, and Culture, Gut, 1998, 43, 128–133 
69. M. Erkan, C. W. Michalski, S. Reider, C. Reiser-Erkan, I. Abiatari, A. Kolb, N. A. Giese, I. 
Esposito, H. Friess, and J. Kleef, The Activated Stroma Index is a Novel and Independent 
Prognostic Marker in Pancreatic Ductal Adenocarcinoma, Clin. Gastroenterol. Hepatol., 2008, 
6, 1155-1161C.  
70. C. Zu and J. Wang, Tumor-Colonizing Bacteria: A Potential Tumor Targeting Therapy, Crit. 
Rev. Microbiol., 2014, 40, 225-235 
71. M. W. Dewhirst, Y. Cao and B. Moeller, Cycling Hypoxia and Free Radicals Regulate 
Angiogenesis and Radiotherapy Response, Nat. Rev. Cancer, 2008, 8, 425-437 
72. A. T. St Jean, M. Zhang, N. S. Forbes, Bacterial Therapies: Completing the Cancer Treatment 
Toolbox, Curr. Opin. Biotechnol., 2008, 19, 511-517  
73. P. Lehouritis, J. Cummins, M. Stanton, C.T. Murphy, F.O. McCarthy, G. Reid, C. Urbaniak, 
W.L. Byrne, M. Tangney, Local Bacteria Affect the Efficacy of Chemotherapeutic Drugs. Sci. 
Rep., 2015, 5, 14554 
74. P. R. Hsueh, New Delhi Metallo-b-lactamase-1 (NDM-1): An Emerging Threat Among 
Enterobacteriaceae, J. Formos. Med. Assoc., 2010, 109, 685–687 
75. D. R. Monteiro, L. F. Gorup, A. S. Takamia, A. C. Ruvollo- Filho, E. R. De Camargo and D. B. 
Barbosa, The Growing Importance of Materials that Prevent Microbial Adhesion: Antimicrobial 
Effect of Medical Devices Containing Silver. Int. J. Antimicrob. Agents, 2009, 34, 103–110. 
76. Woodrow Wilson Database, An Inventory of Nanotechnology Based Consumer Products 
Currently on the Market, 2011, http://www.nanotechproject.org/inventories/consumer/ analysis 
_draft/.  
77. X. Z. Lin, X. Teng and H. Yang, Direct Synthesis of Narrowly Dispersed Silver Nanoparticles 
Using a Single-Source Precursor, Langmuir, 2003, 19, 10081–10085. 
78. Y. Tan, X. Dai, Y. Li and D. Zhu, Preparation of Gold, Platinum, Palladium and Silver 
Nanoparticles by the Reduction of their Salts with a Weak Reductant–Potassium Bitartrate. J. 
Mater. Chem., 2003, 13, 1069–1075. 
79. J. Yang, H. Yin, J. Jia and Y. Wei, Controlled Particle Growth of Silver Sols through the Use of 
Hydroquinone as a Selective Reducing Agent. Langmuir, 2011, 27, 5047– 5053. 
80. J. A. Creighton, C. G. Blatchford and M. G. Albrecht, Plasma Resonance Enhancement of 
Raman Scattering by Pyridine Adsorbed on Silver or Gold Sol Particles of Size Comparable to 
the Excitation Wavelength. J. Chem. Soc., Faraday Trans. 2, 1979, 75, 790–798. 
81. A. Pyatenko, M. Yamaguchi and M. Suzuki, Synthesis of Spherical Silver Nanoparticles with 
Controllable Sizes in Aqueous Solutions. J. Phys. Chem. C, 2007, 111, 7910–7917. 
82. V. K. Sharma, R. A. Yngard and Y. Lin, Silver Nanoparticles: Green Synthesis and their 
Antimicrobial Activities. Adv. Colloid Interface Sci., 2009, 145, 83–96. 
83. J. Thiel, L. Pakstis, S. Buzby, M. Raffi, C. Ni, D. J. Pochan and S. I. Shah, Antibacterial 
Properties of Silver-Doped Titania. Small, 2007, 3, 799–803. 
84. R. R. Arvizo, S. Bhattacharyya, R. A. Kudgus, K. Giri, R. Bhattacharya and P. Mukherjee, 
Intrinsic Therapeutic Applications of Noble Metal Nanoparticles: Past, Present and Future. 
Chem. Soc. Rev., 2012, 41, 2943–2970. 
85. S. Agnihotri, S. Mukherji and S. Mukherji, Size-Controlled Silver Nanoparticles Synthesized 
over the range 5–100 nm using the Same Protocol and Their Antibacterial Efficacy. RSC 
Advances, 2013, 4, 3974-3983. 
86. H. K. Lim, R. L. Gurung and M. P. Hande, DNA-Dependent Protein Kinase Modulates the 
Anti-Cancer Properties of Silver Nanoparticles in Human Cancer Cells, Mutat. Res. Genet. 
Toxicol. Environ. Mutagen., 2017, 824, 32-41  
87. D. Guo, L. Zhu, Z. Huang, H. Zhou, Y. Ge, W. Ma, J. Wu, X. Zhang, X. Zhou, Y. Zhang, Y. 
Zhao and N. Gu, Anti-Leukemia Activity of PVP-Coated Silver Nanoparticles via Generation of 
Reactive Oxygen Species and Release of Silver Ions, Biomater., 2013, 34, 7884-7894  
88. M. A. Franco-Molina, E. Mendoza-Gamboa, C. A. Sierra-Rivera, R. A. Gómez-Flores, P. 
Zapata-Benavides, P. Castillo-Tello, J. M. Alcocer-González, D. F. Miranda-Hernández, R. S. 
Tamez-Guerra and C. Rodríguez-Padilla, Antitumor Activity of Colloidal Silver on MCF-7 
Human Breast Cancer Cells, J. Exp. Clin. Cancer Res., 2010, 29, 148–154 
89. R. Foldbjerg, D. A. Dang and H. Autrup, Cytotoxicity and Genotoxicity of Silver Nanoparticles 
in the Human Lung Cancer Cell Line, A549, Arch. Toxicol., 2011, 85, 743–750 
90. S. Kim, J. E. Choi, J. Choi, K. H. Chung, K. Park, J. Yi and D. Y. Ryu, Oxidative Stress-
Dependent Toxicity of Silver Nanoparticles in Human Hepatoma Cells, Toxicol. In Vitro, 2009, 
23, 1076-1084 (B) 
91. E. Zielinska, A. Zauszkiewicz-Pawlak, M. Wojcik and I. Inkielewicz-Stepniak, Silver 
Nanoparticles of Different Sizes Induce a Mixed Type of Programmed Cell Death in Human 
Pancreatic Ductal Adenocarcinoma, Oncotarget, 2018, 9, 4675-4697 
92. D. H. Lim, J. Jang, S. Kim, T. Kang, K. Lee and I. H. Choi, The Effects of Sub-Lethal 
Concentrations of Silver Nanoparticles on Inflammatory and Stress Genes in Human 
Macrophages using cDNA Microarray Analysis, Biomater., 2012, 33, 4690-4699 
93. S. Arora, J. jain, J. M. Rajwade and K. M. Pakinar, Cellular Responses Induced by Silver 
Nanoparticles: In vitro studies, Toxicology Letters, 2008, 179, 93-100 
94. M. I. Sriram, S. B. Kanth, K. Ka.ishwaralal and S. Gurunathan, Antitumor Activity of Silver 
Nanoparticles in Dalton’s Lymphoma Ascites Tumor Model, Int. J. Nanomedicine, 2010, 5, 
753-762 
95. E. Barcińska, J. Wierzbicka, A. Zauszkiewicz-Pawlak, D. Jacewicz, A. Dabrowska and Iwona 
Inkielewicz-Stepniak, Role of Oxidative and Nitro-Oxidative Damage in Silver Nanoparticles 
Cytotoxic Effect against Human Pancreatic Ductal Adenocarcinoma Cells, Oxid. Med. Cell. 
Longev., 2018, 2018, 8251961(1-15) 
96. Y. G. Yuan, Q. L. Peng and S. Gurunathan, Silver Nanoparticles Enhance the Apoptotic 
Potential of Gemcitabine in Human Ovarian Cancer Cells: combination therapy for effective 
cancer treatment, Int. J. Nanomedicine, 2017, 12, 6487-6502 
97. A. Dziedzic, R. Kubina, R. J. Bułdak, M. Skonieczna and K. Cholewa, Silver Nanoparticles 
Exhibit the Dose-Dependent Anti-Proliferative Effect against Human Squamous Carcinoma 
Cells Attenuated in the Presence of Berbine, Molecules, 2016, 21, 365(1-17) 
98. K. B. Holt and A. J. Bard, Interaction of Silver(I) Ions with the Respiratory Chain of 
Escherichia Coli: An Electrochemical and Scanning Electrochemical Microscopy Study of the 
Antimicrobial Mechanism of Micromolar Ag+, Biochemistry, 2005, 44, 13214-13223C.  
99. C. N. Lok, C. M. Ho, R. Chen, Q. Y. He, W. Y Yu, H. Sun, P. K. Tam, J. F. Chiu, and C. M. 
Che, Silver Nanoparticles: Partial Oxidation and Antibacterial Activities, J. Biol. Inorg. Chem., 
2007, 12, 527-534 
100. M. Marini, S. De Niederhausern, R. Iseppi, M. Bondi, C. Sabia, M. Toselli and F. Pilati, 
Antibacterial Activity of Plastics Coated with Silver-Doped Organic-Inorganic Hybrid Coatings 
Prepared by Sol-Gel Processes, Biomacromolecules, 2007, 8, 1246–1254  
101. S. Shrivastava, T. Bera, A. Roy, G. Singh, P. Ramachandrarao, and D. Dash, 
Characterization of Enhanced Antibacterial Effects of Novel Silver Nanoparticles, 
Nanotechnology, 2007, 18, 225103 (9pp) 
102. M. Jeyaraj, G. Sathishkumar, G. Sivanandhan, D. MubarakAli, M. Rajesha R. Arun, G. 
Kapildev, M. Manickavasagam, N. Thajuddin, K. Premkumar, and A. Ganapathi, Biogenic 
Silver Nanoparticles for Cancer Treatment: An Experimental Report, Colloids and Surfaces B: 
Biointerfaces, 2013, 106, 86-92 
103. P. Swain, S. K. Nayak, A. Sasmal, T. Behera, S. K. Barik, S. K. Swain, S. S. Mishra, A. K. 
Sen, J. K. Das, and P. Jayasankar, Antimicrobial Activity of Metal Based Nanoparticles Against 
Microbes Associated with Diseases in Aquaculture, World J. Microbiol. Biotechnol., 2014, 30, 
2491-2502J.  
104. L. Lu, R. W. Sun, R. Chen, C. K. Hui, C. M. Ho, J. M. Luk, G. K. Lau, and C. M. Che, 
Silver Nanoparticles Inhibit Hepatitis B Virus Replication, Antivir. Ther., 2008, 13, 253-262 
105. I. Papp, C. Sieben, K. Ludwig, M. Roskamp, C. Böttcher, S. Schlecht, A. Herrmann, and R. 
Haag, Inhibition of Influenza Virus Infection by Multivalent Sialic‐Acid‐Functionalized Gold 
Nanoparticles, Small, 2010, 6, 2900-2906 
106. J. L. Elechiguerra, J. L. Burt, J. R. Morones, A. Camacho-Bragado, X. Gao, H. H. Lara, and 
M. J. Yacaman, Interaction of Silver Nanoparticles with HIV-1, J. Nanobiotechnol., 2005, 29, 
3–6. 
107. H. H. Lara, N. V. Ayala-Nuñez, L. Ixtepan-Turrent, and C. Rodriguez-Padilla, Mode of 
Antiviral Action of Silver Nanoparticles Against HIV-1, J. Nanobiotechnol., 2010, 8, 1-10 
108. S. W. Kim, J. H. Jung, K. Lamsal, Y. S. Kim, J. S. Min, and Y. S. Lee, Antifungal Effects of 
Silver Nanoparticles (AgNPs) against Various Plant Pathogenic Fungi, Mycobiology, 2012, 40, 
53-58 
109. G. A. Martínez-Castañón, N. Niño-Martínez, F. Martínez-Gutierrez, J. R. Martínez-
Mendoza, F. Ruiz, Synthesis and Antibacterial Activity of Silver Nanoparticles with Different 
Sizes, J. Nanopart. Res., 2008, 10, 1343-1348 
110. J. Morones, J. L. Elechiguerra, A. Camacho, K. Holt, J. B. Kouri, J. T. Ramírez and M. J. 
Yacaman, The Bactericidal Effect of Silver Nanoparticles, Nanotechnology, 2005, 16, 2346–
2353 
111. A. M. Fayaz, K. Balaji, M. Girilal, R. Yadav, P. T. Kalaichelvan and R. Venketesan, 
Biogenic Synthesis of Silver Nanoparticles and Their Synergistic Effect with Antibiotics: A 
Study Against Gram-Positive and Gram-Negative Bacteria, Nanomedicine: NBM, 2010, 6, 103–
109 
112. A. R. Shahverdi, A. Fakhimi, H. R. Shahverdi and S. Minaian, Synthesis and Effect of 
Silver Nanoparticles on the Antibacterial Activity of Different Antibiotics Against 
Staphylococcus Aureus and Escherichia Coli, Nanomedicine: NBM, 2007, 3, 168-171 
113. A. N. Brown, K. Smith, T. A. Samuels, J. Lu, S. O. Obare, and M. E. Scott, Nanoparticles 
Functionalized with Ampicillin Destroy Multiple-Antibiotic-Resistant Isolates of Pseudomonas 
Aeruginosa and Enterobacter Aerogenes and Methicillin-Resistant Staphylococcus Aureus, 
Environ. Microbiol. 2012, 78, 2768–2774 
114. G. Chen, J. Lu, C. Lam and Y. Yu, A Novel Green Synthesis Approach for Polymer 
Nanocomposites Decorated with Silver Nanoparticles and their Antibacterial Activity, Analyst, 
2014, 139, 5795-5799 
115. S. Shankar, L. F. Wang and J. W. Rhim, Preparations and Characterization of 
Alginate/Silver Composite Films: Effect of Types of Silver Particles, Carbohydr. Polym., 2016, 
146, 208-216 
116. C. Acharya, C. R. Panda, P. K. Bhaskara, A. Sasmal, S. Shekhar and A. K. Sen, 
Physicochemical and Antimicrobial Properties of Sodium Alginate/Gelatin-Based Silver 
Nanoformulations, Polym. Bull., 2017, 74, 689-706 
117. H. Kong and J. Jang, Antibacterial Properties of Novel Poly(methyl methacrylate) Nanofiber 
Containing Silver Nanoparticles, Langmuir, 2008, 24, 2051-2056  
118.  A. Manzur, A. Oluwasamni, D. Moss, A. Curtis, C. Hoskins, Nanotechnologies in 
Pancreatic Cancer, Pharmaceutics, 2017, 9, 39 
119.  M. Au, T.I. Emeto, J. Power, V.N. Vangaveti, H.C. Lai, Emerging Therapeutic Potential of 
Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials, Biomedicines, 
2016, 4, 20 
120.  J. Zhou, J. Wang, Q. Xu, S. Xu, J. Wen, Z. Yu, D. Yang, Folate-Chitosan-Gemcitabine 
Core-Shell Nanoparticles Targeted to Pancreatic Cancer, Chin. J. Can. Res., 2013, 25, 527-535 
121.  S. Ji, J. Xu, B. Zhang, W. Yao, W. Xu, W. Wun, Y. Xu, H. Wang, Q. Ni, H. Hou, X. Yu, 
RGD-Conjugated Albumin Nanoparticles as a Novel Delivery Vehicle in Pancreatic Cancer 
therapy, Cancer Biol. Ther., 2012, 13, 206-215 
122.  S-t. Wu, A.J. Fowler, C.B. Garmon, A.B. Fessler, J.D. Ogle, K.R. Grover, B.C. Allen, C.D. 
Williams, R. Zhou, M. Yazdanifar, C.A. Ogle, P. Mukherjee, Treatment of Pancreatic Ductal 
Adenocarcinoma with Tumor Antigen Specific-Targeted Delivery of Paclitaxel Loaded PLGA 
Nanoparticles, BMC Cancer, 2018, 18, 457 
123. M. Malekigorji, M. Alfahad, P. Kong Thoo Lin, S.M. Jones, A. Curtis, C. Hoskins, 
Thermally Triggered Theranostics for Pancreatic Cancer Therapy, Nanoscale, 2017, 9, 12735-
12745. 
124. A. Oluwasanmi, W. Al-Shakarchi, A. Manzur, M.H. Aldebasi, R.S. Elsini, M.K. Albusair, 
K.J. Haxton, A.D.M. Curtis, C. Hoskins, Diels Alder- Mediated Release of Gemcitabine from 
Hybrid Nanoparticles for Enhanced Pancreatic Cancer Therapy, J. Control. Release, 2017, 266, 
355-364 
125.  S.C. Coelho, D.P. Reis, M.C. Pereira, M.A.N. Coelho, Gold Nanoparticles for Targeting 
Varlitnib to Human Pancreatic Cancer Cells, Pharmaceutics, 2018, 10, 91  
126. Y. Wang, B.B. Newell, J. Irudayaraj, Folic Acid Protected Silver Nanocarrieris for Targeted 
Drug Delivery, J. Biomed. Nanotechnol. 2012, 8, 751-759 
127. H. Padinjarathil, M. M. Joseph, B. S. Unnikrishnan, G. U. Preethi, R. Shiji, M. G. Archana, 
S. Maya, H. P. Syama and T. T. Sreelekha, Galactomannan Endowed Biogenic Silver 
Nanoparticles Exposed Enhanced Cancer Cytotoxicity with Excellent Biocompatibility, Int. J. 
Biol. Macromol., 2018, 118, 1174-1182 
128. A. R. Zlotta et al., Percutaneous Transperineal Radiofrequency Ablation of Prostate Tumor: 
Safety, Feasibility and Pathological Effects on Human Prostate Cancer, British J. Urology, 
1998, 81, 265-275 
129. A. Gillams, Tumor Ablation: Current Role in the Kidney, Lung and Bone, Cancer Imaging, 
2009, 9, S68-S70 
130. R. Girelli, I. Frigerio, R. Salvia, E. Barbi, P. Tinazzi Martini and C. Bassi, Feasibility and 
Safety of Radiofrequency Ablation for Locally Advanced Pancreatic Cancer, British Journal of 
Surgery, 2010, 97, 220-225 
131. M. S. Sabel, M. A. Nehs, G. Su, K. P. Lowler, J. L. Ferrara and A. E. Chang, Immunologic 
Response to Cryoablation of Breast Cancer, Breast Cancer Res Treat., 2005, 90, 97-104 
132. A. Oto, I. Sethi, G. Karczmar, R. McNichols, M. K. Ivancevic, W. M. Stadler, S. Watson 
and S. Eggener, MR Imaging-Guided Focal Laser Ablation for Prostate Cancer: Phase I Trial, 
Radiology, 2013, 267, 932-940 
133. A. Shagan, T. Croitoru-Sadger, E. Crem-Salkmon and B. Mizrahi, Near-Infrared Light 
Induced Phase Transition of Biodegradable Composites for On-Demand Healing and Drug 
Release, ACS Appl. Mater. Interfaces, 2018, 10, 4131-4139 
134. D. B. Chithrani, S. Jelveh, F. Jalali, M. van Prooijen, C. Allen, R. G. Bristow, R. P. Hill and 
D. A. Jaffray, Gold Nanoparticles as Radiation Sensitisers in Cancer Therapy, Radiation 
Research, 2010, 173, 719-728 
135. N. Chattopadhyay, Z. Cai, Y. L. Kwon, E. Lechtman, J. P. Pignol and R. M. Reilly, 
Molecularly Targeted Gold Nanoparticles Enhance the Radiation Response of Breast Cancer 
Cells and Tumor Xenografts to X-radiation, Breast Cancer Res. Treat., 2013, 137, 81-91 
136. J. Swanner, J. Mims, D.L. Carroll, S.A. Akman, C.M. Furdui, S.V. Torti, R.N. Sigh 
Differential Cytotoxic and Radiosensitizing Effects of Silver Nanoparticles on Triple-Negative 
Breast Cancer and Non-Triple Negative Cells, Int. J. Nanomed., 2015, 10, 3937-3953. 
137. R. Lu, D. Yang, D. Cui, Z. Wang, L. Guo, Egg White-Mediated Green Synthesis of Silver 
Nanoparticles with Excellent Biocompatibility and Enhanced Radiation Effects on Cancer Cells, 
Int. J. Nanomed. 2012, 7, 2101-2107 
138. P. Liu, H. Jin, Z. Guo, J. Ma, J, Ma, D. Li, H. Wu, N. Gu, Silver Nanoparticles Outperform 
Gold Nanoparticles in Radiosensitizing U251 Cells In Vitro and in an Intracranial Mouse Model 
of Glioma, Int. J. Nanomed., 2016, 11, 5003-5014 
139. M. Skonieczna and D. Hudy, Biological activity of Silver Nanoparticles and their ap-
plications in Anticancer Therapy, Silver Nanoparticles 2018. 
140. P. V. AshaRani, G. L. K. Mun, M. P. Hande and S. Valiyaveettil, Cytotoxicity and 
Genotoxicity of Silver Nanoparticles in Human Cells, ACS Nano, 2009, 3, 279-290 
 
Figure legends 
Figure 1. Chemical structure of gemcitabine. 
Figure 2. Pancreatic cancer microenvironment. The tumor microenvironment consists of numerous 
cell types and extracellular matrix, which collectively affect drug delivery. Pancreatic cancer is 
notably characterized by fibrosis separating cancer cells from blood vessels. The dotted arrow 
shows the path than an i.v. given nanoparticle must travel to reach cancer cells and achieve its 
effects [40]. 
Figure 3. Antibiotics enhance the anticancer activity of gemcitabine in a mouse model of colon 
carcinoma. (A) A subcutaneous model of colon carcinoma (MC-26 cells) was established in 
immunocompetent BALB/c mice. Bacteria expressing luciferase were injected intravenously and 
selectively detected in the tumors with IVIS. (B and C) E. coli Nissle 1917 (5 × 106 bacteria) were 
injected into the tail vein of mice with MC-26 tumors. The antibiotic ciprofloxacin (Cipro) (150 
mg/kg) was administered intraperitoneally (every 12 hours), and gemcitabine (Gem) (150 mg/kg) 
was administered on days 0 and 4. The antibiotic prevented bacterial growth (B) and increased the 
efficacy of the chemotherapy [(C) Left panel, no significant difference; right panel, ***P < 0.001 
by two-way analysis of variance (ANOVA) with a Bonferroni adjustment]. N = 16 to 18 mice 
(groups without Cipro) and 9 to 13 mice (groups with Cipro). Tumor size was normalized to the 
tumor size on day 0. Bars represent standard error of the mean. (D) WT E. coli or CDD-deficient E. 
coli (DCDD) were injected into the tail vein of mice with MC-26 tumors. Gemcitabine was 
administered intraperitoneally (150 mg/kg) on days 0 and 4. Gemcitabine significantly inhibited 
tumor growth when DCDD bacteria rather than WT bacteria were administered (*P < 0.05 by two-
way ANOVA with a Bonferroni adjustment). N = 15 mice (WT – Gem), 6 to 8 mice (WT + Gem), 
10 mice (DCDD – Gem), and 4 to 6 mice (DCDD + Gem). Tumor size was normalized to the tumor 
size on day 0. Bars represent standard error of the mean. (E) Devices for local intratumor release of 
drug microdoses were used to release gemcitabine and antibiotics, alone and in combination, 
directly into the microenvironment of bacteria-colonized tumors to assess in vivo efficacy (13). 
Histological staining by cleaved caspase 3 shows significantly more apoptosis when gemcitabine is 
released in combination with antibiotics (ii and iv) but less apoptosis when gemcitabine (i) or 
ampicillin (iii) is administrated alone. Scale bars, 200 mm [29]. 
Figure 4. PANC-1 cells treated with 2.6 nm AgNPs. AgNPs triggered both apoptotic and non-
apoptotic cell death at 2.5 μg/ mL (A-C) and 3.5 μg/mL (D) concentration. The evidence of both 
apoptotic (arrow) and necrotic/necroptotic (black arrow head) cell morphology have been found (a 
and b). Apoptotic cell with typical nuclear condensation (N), blebbing (asterisk) (b). The 
necroptotic cell death was preceded by intensive cytoplasm vacuolization (v), nuclear membrane 
dilatation (white arrow heads) and disrupted cellular membrane ad cytoplasmic swelling (a, c and 
d). Final stage of cellular death, degradation of cell organelles and cytoplasm (d). Loss of cell 
membrane integrity, chromatin condensation of nucleus (N). The representative cell is shown, 
presenting final stage of cellular death, degradation of cell organelles and cytoplasm, total loss of 
cell membrane integrity. However, the nuclear membrane integrity was maintained, the nucleus (N) 
was condensed, with peripheral clumps of heterochromatin. At this level of cell damage it was 
impossible to specify the cell death pathway. Magnifications: a ×2000; b ×4000; c ×5000; d ×6000 
[91]. 
Figure 5. Schematic representation of mechanisms of action of silver nanoparticle antimicrobial 
effect.  
Figure 6. Schematic representation of active transport of nanoparticles into cells.  
Figure 7. In vivo evaluation on BxPC-3 xenograft models in Nu/Nu female mice (4-6 weeks old) 
dosed once a week at 3 mgKg-1 for 4 weeks. A) Comparison of tumor volume over study duration∞ 
Study stopped before completion due to tumor volume approaching maximum humane volume (0.9 
cm3). B) Comparison of tumors after excision: 1) control, 2) control with laser irradiation, 3) HNP, 
4) HNP with laser irradiation, 5) GEM, 6) GEM with laser irradiation, 7) HNP-L-GEM, 8) HNP-L-
GEM with laser irradiation. Where laser irradiation was required this was carried out 24 h after 
dosing under anaesthetic. The tumor was irradiated at 1064 nm as for 20 sec using a ML-LASER-
YB5 Q-switched Nd:YAG Laser Treatment System. Pulse width: 10 ns, pulse repetition frequency: 
6 Hz, laser spot diameter: 3 mm, cooling system: water cooled with airflow cooling. The beam was 
collimated through concave lenses to a 1 mm diameter. C) Comparison of tumor weight after 
excision * denotes significance compared to controls, ** denotes significance compared to GEM, 
*** denotes significance compared to HNP-L-GEM without laser irradiation (p<0.01) (n=5, ±SE) 
[124].  
 
 
 
 
 
 
 
 
  
Tables 
Table 1.  A summary of the clinical trials comparing new treatment strategies to gemcitabine, or 
other gemcitabine-based therapeutics. 
 
 
 
 
 
 
 
 
 
 
Author(s) Date Treatment Clinical 
Trial 
Phase(s) 
Change in 
PFS 
Overall 
survival 
Ref. 
Reni et al 2005 Gemcitabine, 5-FU, cisplatin, 
epirubicin vs. gemcitabine  
III 4 months: 
60% vs 
28%   
2 year: 
11.5% vs 
2.1% 
[30] 
Cunningham 
et al 
2009 Gemcitabine, capecitabine vs. 
gemcitabine 
II/III 5.3 vs 3.8 
months 
Median: 7.1 
vs 6.2 
months 
[31] 
Conroy et al 2011 Folinic acid, irinotecan, 
oxaliplatin vs. gemcitabine 
II/III 6.4 vs. 3.3 
months 
11.1 vs 6.8 
months 
[33] 
Von Hoff et 
al 
2013 Gemcitabine, nab-paclitaxel 
vs. gemcitabine 
III 5.5 vs 3.7 
months  
8.5 vs 6.7 
months 
[34] 
Reni et al 2016 Gemcitabine-nab-paclitaxel, 
cisplatin, capecitabine vs nab-
paclitaxel-gemcitabine 
II 12.5 vs 9.9 
months 
20.7 vs. 
19.1 months 
[35] 
  
 
 
 
 
 
 
 
 
 
Table 2.  A summary of different silver nanoparticle-based treatments, tested on either cell culture 
or in a xenografted mouse model. 
 
Author(s) Date Treatment(s) Cancer Type 
Mouse 
model 
Cell 
lines 
Results Ref. 
Zielinska et 
al. 
2018 
AgNPs, 
gemcitabine 
Pancreatic No 
PANC-
1, 
hTERT 
Greater cytotoxicity 
against cancer cell line 
than non-cancerous. 
AgNPs had a better 
effect than 
gemcitabine during 
testing 
[91] 
Guo et al. 2013 AgNPs 
Acute 
myeloid 
leukaemia 
No 
DAMI, 
HEL, 
HL-60, 
NB4, 
SHI-1, 
THP-1 
Dose-dependent 
reduction in cell 
viability, with THP-1 
cells being most 
sensitive and SHI-1 
the least sensitive to 
AgNPs. 
[87] 
Lim et al. 2017 AgNPs - No U937 
Size-dependent effect 
of AgNPs on toxicity, 
smaller NPs had 
greater cytotoxic 
effects at lower 
concentrations. 
Apoptosis and DNA 
damage. 
[92] 
Arora et al. 2008 AgNPs 
Human skin 
carcinoma, 
human 
fibrosarcoma 
No 
A431, 
HT-
1080 
Both cell types 
showed dose-
dependent 
cytotoxicity. 
Apoptosis induced at 
different concentration 
ranges. Fucntional 
damage caused. 
[93] 
Lim, 
Gurung 
and Hande 
2017 AgNPs 
Glioblastoma 
and Breast 
Cancer 
No 
U257                        
MCF-
7, 
MDA-
MB-
231 
Cytoskeletal 
deformities in cell 
lines. Shape changes 
in the cancer cells. 
Reduction of cell 
proliferation in cancer 
[86] 
cells, caused DNA 
damage, cell death and 
reduced c-Myc 
expression. 
Sriram et 
al. 
2010 AgNPs 
Dalton's 
Lymphoma 
Yes DLA 
Tumour volume 
decrease of 68.5% 
using AgNP treatment 
[94] 
Barcińska 
et al. 
2018 AgNPs Pancreatic No 
PANC-
1, 
hTERT 
Increased nitric oxide 
concentration present 
in PANC-1 cell line. 
[95] 
Yuan, Peng 
and 
Gurunathan 
2017 
AgNP + 
gemcitabine 
Ovarian No A2780 
A strong synergistic 
effect was seen, with 
lower concentrations 
of AgNPs required to 
successfully cause 
cytotoxicity to the cell 
line 
[96] 
Dziedzic et 
al. 
2016 
AgNP + 
berberine 
Human 
squamous 
carcinoma 
cells 
No 
SCC-
23 
(ATCC 
CRL-
1628) 
Dose and time 
dependent effect over 
24 and 48 hours. 
Berberine had a more 
inhibitory effect on the 
actions of AgNPs. 
[97] 
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